Jasper reports 67% complete response at week 12 in additional BEACON CSU patients; dose selected for Phase 2b

Jasper Therapeutics, Inc.

67% (4/6) of new BEACON briquilimab patients achieved complete response at week 12; mean UAS7 drop of 31 points.
In open-label extension, 58% of 36 CSU patients achieved complete response and 75% achieved CR or well-controlled at week 12.
Median follow-up of 205 days in 63 patients; KIT-related AEs were infrequent, low-grade, and resolved without discontinuation.
Company plans to commence Phase 2b study of briquilimab in CSU in second half of 2026.
Briquilimab is an investigational anti-KIT antibody targeting mast-cell-driven diseases like CSU and CIndU.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.